ScreenerHero

NVCT Nuvectis Pharma, Inc.

NAS · US · Healthcare · Biotechnology · nuvectis.com
20.29USD+1.30%Mkt Cap: 662.35M $P/E: —

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NX…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap662.35M USD
Enterprise Value630.45M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.44M USD
Revenue/Share—
Last Price20.29 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-20.86
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B58.91
EPS (TTM)-1.31
EPS (Forward)-0.96
52W Range
5.55062% of range29.27
52W High29.27 USD
52W Low5.550 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-143.61%
ROA-83.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.01M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.34%
Net Debt-22.16M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.68
Quick Ratio1.67
Book Value/Sh0.34 USD
Cash/Share0.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.40 USD
Upside (mean)+74.5%
Target Range30.00 USD – 40.00 USD
30.00+74.5% to mean40.00
# Analysts5
Ownership
Shares Out.32.64M
Float21.20M
Insiders34.43%
Institutions33.57%
Short Interest
Short Ratio11.7d
Short % Float10.88%
Short % Out.7.24%
Shares Short2.36M
Short (prev mo.)1.84M
Technical
SMA 5021.79 (-6.9%)
SMA 20013.54 (+49.9%)
Beta-0.24
S&P 52W Chg16.45%
Avg Vol (30d)206.03K
Avg Vol (10d)185.15K
Technical Indicators
RSI (14)44.4
MACD-0.3045
MACD Signal-0.0683
MACD Hist.-0.2362
BB Upper24.18 USD
BB Middle21.76 USD
BB Lower19.34 USD
BB Width22.24%
ATR (14)1.521 USD
Vol Ratio (20d)0.58x